Ralf Lorenz - Concepedia

Author

Ralf Lorenz

Also Known As

Carola Loock, Dimitrios Plakias, Helmut Forstbauer, Lorenz, R., M. Wolfgarten, Martin Loss, R Lorenz, R. Lorenz, RALF LORENZ, Ralf Lorenz

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Ludwig-Maximilians-Universität München Heinrich Heine University Düsseldorf Universität Hamburg University Medical Center Hamburg-Eppendorf University Hospital Ulm

About

Ralf Lorenz is an author at Ludwig-Maximilians-Universität München specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	624
2	Health Sciences	3	3	72
3	Engineering	1	1	11
4	Public Health	1	1	25
5	Anatomy	1	1	46

Ralf Lorenz

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients Brigitte Rack, Christian Schindlbeck, Julia Jückstöck, JNCI Journal of the National Cancer Institute	2014	601
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial Jacobus Pfisterer, Catherine Shannon, Klaus Baumann, The Lancet Oncology MedicineMetronomic TherapyGynecologyRecurrent Ovarian CancerCancer Treatment	2020	157
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial Marco Colleoni, Weixiu Luo, Per Karlsson, The Lancet Oncology Breast OncologyMedicineCancer ManagementGynecologyBreast Cancer	2017	120
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Radoslav Chekerov, Felix Hilpert, Sven� Mahner, The Lancet Oncology OncologyMedicineMetronomic TherapyClinical TrialsGynecology	2018	108
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group Jalid Sehouli, Dirk Stengel, Philipp Harter, Journal of Clinical Oncology	2010	103
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial Michail Ignatiadis, Saskia Litière, Françoise Rothé, Annals of Oncology	2018	69
CYTOMEGALOVIRUS EARLY PROMOTER INDUCED EXPRESSION OF hCD59 IN PORCINE ORGANS PROVIDES PROTECTION AGAINST HYPERACUTE REJECTION1 Heiner Niemann, Els Verhoeyen, K Wonigeit, Transplantation	2001	65
Abstract S6-5: Prognostic Relevance of Circulating Tumor Cells in the Peripheral Blood of Primary Breast Cancer Patients B Rack, Christian Schindlbeck, Ulrich Andergassen, Cancer Research Surgical OncologyBreast OncologyCirculating Tumor CellsCancer ManagementImmunology	2010	51
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment Thomas W. P. Friedl, Tanja Fehm, Volkmar Müller, JAMA Oncology	2021	49
Functional Tissue Engineering of Autologous Tunica Albuginea: A Possible Graft for Peyronie’s Disease Surgery D. Schultheiss, Ralf Lorenz, Roland Meister, European Urology Tissue EngineeringRegenerative MedicineSoft Tissue SurgeryReconstructive SurgeryDisease Surgery	2004	46

Page 1